Last checked at 19 Aug 2010 17:20
| Issued: 19th August 2010, London, U.K. |
|
|
| GlaxoSmithKline Capital plc |
|
|
|
|
| Results announcement and interim management report for the half year ended 30th June 2010 |
| Performance GlaxoSmithKline Capital plc ("the Company"), a wholly owned subsidiary of GlaxoSmithKline plc, provides financial services to GlaxoSmithKline plc and its subsidiaries (the "Group"). During the period the Company made a profit on ordinary activities after taxation of £1,455,000 (H1 2009: £1,211,000).
The Company seeks to denominate borrowings in the currencies of its principal assets and cash flows. These are primarily denominated in Euros and Sterling.
The policy on interest rate risk management limits the amount of floating interest payments to a prescribed percentage of trading profit.
After making certain enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing this document, due to ongoing support from the intermediate parent undertaking, GlaxoSmithKline Finance plc.
|
| Outlook The Directors are of the opinion that the current level of activity and the period end financial position are satisfactory and will remain so in the foreseeable future. |
|
|
| GlaxoSmithKline Capital plc, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom. Registered in England and Wales. Registered number: 2258699 |
| GlaxoSmithKline Capital plc |
| Profit and loss account |
| Six months ended 30th June 2010 |
|
| Period ended 30th June 2010 £'000 | Period ended 30th June 2009 £'000 | Year ended 31st December 2009 £'000 |
|
| ------ | ------ | ------ |
| Net administrative income (including foreign exchange gains and losses) | 599 | 982 | 668 |
|
| ------ | ------ | ------ |
|
|
|
|
|
| Interest payable and similar charges | (196,694) | (174,285) | (393,445) |
| Interest receivable and similar income | 198,058 | 174,985 | 395,932 |
|
| ------ | ------ | ------ |
| Net interest receivable | 1,364 | 700 | 2,487 |
|
|
|
|
|
| Operating profit | 1,963 | 1,682 | 3,155 |
|
| ------ | ------ | ------ |
| Profit on ordinary activities before taxation | 1,963 | 1,682 | 3,155 |
|
|
|
|
|
| Taxation | (508) | (471) | (884) |
|
| ------ | ------ | ------ |
| Profit on ordinary activities after taxation | 1,455 | 1,211 | 2,271 |
|
| ------ | ------ | ------ |
| Statement of total recognised gains and losses |
| Six months ended 30th June 2010 |
|
| Period ended 30th June 2010 £'000 | Period ended 30th June 2009 £'000 | Year ended 31st December 2009 £'000 |
|
| ------ | ------ | ------ |
| Profit for the period | 1,455 | 1,211 | 2,271 |
|
|
|
|
|
| Cash flow hedge reserve | 206 | 206 | 411 |
| Prior year deferred tax movement in cash flow hedge reserve | - | (58) | - |
|
| ------ | ------ | ------ |
| Total recognised gains and losses | 1,661 | 1,359 | 2,682 |
|
| ------ | ------ | ------ |
| GlaxoSmithKline Capital plc |
| Balance sheet |
|
| 30th June 2010 £'000 | 31st December 2009 £'000 |
|
| --------- | --------- |
| Debtors: amounts due after one year | 8,036,247 | 8,459,794 |
| Debtors: amounts due within one year | 157,078 | 129,868 |
| Cash at bank | 5 | 4 |
|
| --------- | --------- |
| Current assets | 8,193,330 | 8,589,666 |
|
|
|
|
| Creditors: amounts due within one year | (163,755) | (137,563) |
|
| --------- | --------- |
| Net current assets | 8,029,575 | 8,452,103 |
|
| --------- | --------- |
| Total assets less current liabilities | 8,029,575 | 8,452,103 |
|
| --------- | --------- |
| Loans due after one year | (8,036,849) | (8,461,038) |
|
| --------- | --------- |
| Creditors: amounts due after one year | (8,036,849) | (8,461,038) |
|
| --------- | --------- |
| Net liabilities | (7,274) | (8,935) |
|
| --------- | --------- |
|
|
|
|
| Called up share capital | 100 | 100 |
| Profit and loss account | 54 | (1,401) |
| Other reserves | (7,428) | (7,634) |
|
| --------- | --------- |
| Equity shareholders' deficit | (7,274) | (8,935) |
|
| --------- | --------- |
| Reconciliation of movements in equity |
|
| Period ended 30th June 2010 £'000 | Period ended 30th June 2009 £'000 | Year ended 31st December 2009 £'000 |
|
| ------- | ------- | ------- |
| Equity shareholders' deficit at beginning of period | (8,935) | (11,617) | (11,617) |
| Profit for the period | 1,455 | 1,211 | 2,271 |
| Movement in cash flow hedge reserve | 206 | 148 | 411 |
|
| ------- | ------- | ------- |
| Equity shareholders' deficit at end of period | (7,274) | (10,258) | (8,935) |
|
| ------- | ------- | ------- |
| GlaxoSmithKline Capital plc |
| Taxation | Period ended 30th June 2010 £'000 | Period ended 30th June 2009 £'000 | Year ended 31st December 2009 £'000 |
|
| -------- | -------- | -------- |
| Tax charge | 508 | 471 | 884 |
|
|
|
|
|
| Tax rate | 28% | 28% | 28% |
|
|
|
|
|
| The effective tax rate is based on the anticipated charge for taxation for the year to 31st December 2010. | |||
| Net interest receivable | Period ended 30th June 2010 £'000 | Period ended 30th June 2009 £'000 | Year ended 31st December 2009 £'000 |
| Interest payable and similar charges | -------- | -------- | -------- |
| Net swap interest expense | (206) | (206) | (411) |
| Interest on Medium-Term Notes and Eurobonds | (192,591) | (171,083) | (385,814) |
| Amortisation of bond expenses | (3,897) | (2,996) | (7,220) |
|
| -------- | -------- | -------- |
|
| (196,694) | (174,285) | (393,445) |
| Interest receivable and similar income |
|
|
|
| Interest receivable on loans with Group undertakings | 198,058 | 174,985 | 395,932 |
|
| -------- | -------- | -------- |
|
| 1,364 | 700 | 2,487 |
|
| -------- | -------- | -------- |
| Debtors | 30th June 2010 £'000 | 31st December 2009 £'000 |
| Amounts due within one year | --------- | --------- |
| Amounts owed by Group undertakings - current account | 156,239 | 129,145 |
| Deferred tax asset | 839 | 723 |
|
| --------- | --------- |
|
| 157,078 | 129,868 |
|
| --------- | --------- |
| Amounts due after one year |
|
|
| Amounts owed by Group undertakings - loans | 8,036,247 | 8,459,794 |
|
| --------- | --------- |
|
| 8,193,325 | 8,589,662 |
|
| --------- | --------- |
| Other Creditors: amounts due within one year | 30th June 2010 £'000 | 31st December 2009 £'0000 |
|
| -------- | -------- |
| Taxation | (2,197) | (1,648) |
| Other creditors | (161,558) | (135,915) |
|
| -------- | -------- |
|
| (163,755) | (137,563) |
|
| -------- | -------- |
| GlaxoSmithKline Capital plc |
| Net debt | 30th June 2010 £'000 | 31st December 2009 £'0000 |
|
| --------- | --------- |
| Cash at bank | 5 | 4 |
| Amounts owed by Group undertakings - loans | 8,036,247 | 8,459,794 |
|
| --------- | --------- |
|
| 8,036,252 | 8,459,798 |
|
|
|
|
| Loans due after one year |
|
|
| Eurobonds and Medium-Term Notes | (8,036,849) | (8,461,038) |
|
| --------- | --------- |
| Net debt | (597) | (1,240) |
|
| --------- | --------- |
| The Sterling equivalent values of Eurobonds and Medium-Term Notes has decreased due to the depreciation of the Euro against Sterling. The overall exchange gain of £428,086,641 has been partially off-set by the addition of amortised bond costs, which totalled £3,896,780 in the period to 30th June 2010 (year ended 31st December 2009: £7,220,220). |
| Related party transactions
The Company's significant related parties are other members of the Group. Advantage has been taken of the exemption afforded by FRS 8 'Related Party Disclosures' not to disclose any related party transactions within the Group. There are no other related party transactions. |
| Cash flow
As a wholly owned subsidiary of GlaxoSmithKline plc, advantage has been taken of the exemption afforded by FRS 1 'Cash Flow Statements' not to prepare a cash flow statement. |
| Accounting presentation and policies
This unaudited Results Announcement containing condensed financial information for the six months ended 30th June 2010 is prepared under UK GAAP in accordance with the Listing Rules of the UK Listing Authority, pronouncements on interim reporting issued by the Accounting Standards Board (ASB) and the accounting policies set out in the company's audited Financial Statements 2009.
This Results Announcement does not constitute statutory accounts of the company within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The balance sheet at 31st December 2009 has been derived from the full accounts published in the Financial Statements 2009, which have been delivered to the Registrar of Companies and on which the report of the independent auditors was unqualified and did not contain a statement under section 498 of the Companies Act 2006. |
| GlaxoSmithKline Capital plc |
| Principal risks and uncertainties
The directors of GlaxoSmithKline plc manage the risks at a Group level, rather than at an individual business unit level. The principal risks and uncertainties affecting the Company are the same as those which affect the Group and those described under the headings below in the 'Risk Factors' section of the 'Business Review' of the GlaxoSmithKline plc Annual Report 2009. |
|
| Risk that R&D will not deliver commercially successful new products Patent infringement litigation Potential changes in intellectual property laws and regulations Weakness of intellectual property protection in certain countries Risk of substantial adverse outcome of litigation and government investigations Product liability litigation Anti-trust litigation Sales, marketing and regulation Third party competition Governmental and payer controls Regulatory controls Risk of interruption of product supply. Risk from concentration of sales to wholesalers Global political and economic conditions Taxation and treasury Pandemic influenza Environmental liabilities Accounting standards Failure of third party providers Protection of electronic information and assets Alliances and acquisitions Attraction and retention Implementing the Group's strategic priorities |
|
In particular, policies regarding the management of Group risk pertaining to financial risk, interest rate risk and market risk as well as liquidity are discussed in the Group's Annual Report under the Treasury operations section of the 'Business Review'. | |
| Directors' responsibility statement
The Board of Directors approved this document on 19th August 2010.
The Directors confirm that to the best of their knowledge this unaudited condensed financial information has been prepared in accordance with pronouncements by the ASB and that the interim management report herein includes a fair review of the information required by DTR 4.2.7.
The Directors of GlaxoSmithKline Capital plc are Edinburgh Pharmaceutical Industries Limited, Glaxo Group Limited and Mr J S Heslop.
| |
| By order of the Board Paul Blackburn on behalf of Glaxo Group Limited Director |
|
| 19th August 2010 |
|
|
| |
| Internet This Announcement and other information about the GSK Group are available on the website at: http://www.gsk.com. | |